Core Insights - Roche Pharmaceuticals has chosen to extend its partnership with Veeva Systems by adopting Veeva Vault CRM, which is expected to enhance customer engagement through AI capabilities [1][2]. Company Overview - Veeva Systems provides industry cloud solutions for life sciences, offering software, data, and business consulting services to over 1,500 customers, including major biopharmaceutical companies and emerging biotech firms [3]. Partnership Details - The partnership extension will implement Vault CRM across Roche's global Pharma organization, aiming to create more personalized interactions and provide insights to better support healthcare professionals and patients [2]. - Veeva AI, which includes various agentic AI features, will be integrated into the Vault CRM platform, with specific agents like Free Text Agent, Voice Agent, Pre-call Agent, and Media Agent expected to be available in December 2025 [2].

Investment Rating - The report maintains a "Buy" rating for Veeva Systems, suggesting to seize buying opportunities after recent price declines [2][4][8]. Core Insights - Veeva Systems reported strong Q3 FY26 results, with total revenue reaching $811.2 million, representing a 16% year-over-year increase, exceeding market expectations [2][12]. - The company raised its Q4 guidance due to accelerated transactions and strong performance across multiple business lines, particularly in AI and CRM [3][4]. - Veeva's AI initiatives are progressing, with the first AI agents for CRM and commercial content set to launch in December, and further expansion into R&D and quality areas planned for FY26 [3][4]. Financial Performance - Q3 FY26 total revenue was $811.2 million, surpassing the forecast by $9.6 million, with subscription revenue at $682.5 million and professional services at $128.7 million [12]. - Adjusted operating profit margin reached 45%, reflecting a solid profitability performance [2][12]. - The company’s gross margin remained stable at 75%, indicating strong operational efficiency [2]. Market Position and Valuation - Veeva's stock demonstrated resilience, with a smaller decline compared to peers in the AI SaaS sector, highlighting its robust fundamentals [4]. - The intrinsic value of Veeva is estimated at $350.3 per share, indicating a potential upside of approximately 29.5% from the current price of $270.5 [8][28]. - The report notes that Veeva's adjusted P/E ratios for FY26E and FY27E are 44.5x and 38.2x, respectively, which are below the industry average, suggesting a favorable valuation [29]. Growth Outlook - The company aims for a revenue target of $6 billion by 2030, supported by strong demand in the life sciences sector and high customer retention rates [3][4]. - Veeva's growth is expected to be driven by its expanding AI capabilities and the increasing adoption of its cloud solutions in the pharmaceutical industry [3][4].

Core Insights - Veeva Systems, Inc. reported adjusted earnings per share (EPS) of $2.04 for Q3 fiscal 2026, a 16.6% increase from $1.75 year-over-year, surpassing the Zacks Consensus Estimate by 4.62% [1] - Total revenues for the quarter reached $811.2 million, exceeding the Zacks Consensus Estimate by 2.4% and reflecting a 16% year-over-year growth [2] Revenue Details - Subscription services revenues rose 17.5% year-over-year to $682.5 million, driven by both established and new solutions, compared to an estimate of $671 million [3] - Professional services and other revenues increased 13% year-over-year to $128.7 million, surpassing the estimate of $120.1 million [4] Margin Performance - Gross profit improved 16.6% year-over-year to $611.8 million, with a gross margin expansion of 30 basis points to 75.4%, slightly above the predicted 75.3% [5] - Operating profit totaled $240.9 million, a 32.8% increase from the prior year, with an operating margin expansion of 380 basis points to 29.7%, exceeding the predicted 26.7% [7] Financial Position - At the end of Q3 fiscal 2026, the company had cash and cash equivalents and short-term investments of $6.64 billion, up from $6.40 billion at the end of Q2 [8] - Cumulative net cash provided by operating activities was $1.31 billion, compared to $1.02 billion a year ago [8] Guidance - For Q4 fiscal 2026, Veeva expects total revenues between $807 million and $810 million, with subscription revenues estimated at approximately $696 million [11] - The company raised its fiscal 2026 revenue outlook to between $3,166 million and $3,169 million, up from previous guidance of $3,134 million to $3,140 million [12] - Adjusted EPS for fiscal 2026 is now expected to be $7.93, an increase from the previous guidance of $7.78 [14] Strategic Developments - Veeva AI achieved significant milestones during Q3, with plans to release AI agents for CRM and commercial content in early December, and additional agents for R&D and quality in development for 2026 [16][18] - The company strengthened its leadership in CRM, adding 23 new customers, including a major rollout for a top-20 biopharma company in Japan [19] - Veeva Development Cloud saw three top-20 biopharma companies select its applications as their enterprise standard, indicating rising industry confidence [20]

Financial Data and Key Metrics Changes - Total revenue for Q3 was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [6] - CRM now constitutes about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [9] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative, with significant progress expected to benefit customers and the industry [6] - Crossix continues to perform well, with expectations for it to remain a growth driver in the coming years [34][39] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong, with no significant changes in customer buying behaviors noted [31] - Digital marketing spending is increasing, which positively impacts Crossix's business [39] Company Strategy and Development Direction - The company is focused on delivering integrated solutions across clinical operations and clinical data to drive efficiency [11] - Veeva aims to leverage its consulting, data, and software capabilities to provide comprehensive solutions for life sciences [47][48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the industry, citing ongoing demand for innovative solutions to address uncured diseases [31] - The company anticipates no material impact on its 2030 goals despite some customer attrition in the CRM segment [9][75] Other Important Information - The company is investing in product and services teams, which may impact margins in the short term but is expected to yield positive results over time [58] - The partnership with IQVIA is seen as beneficial, enhancing customer confidence and operational capabilities [41][42] Q&A Session Summary Question: Concerns about CRM customer migration - Management acknowledged that CRM is about 20% of total revenue and that attrition is expected to have no immediate impact on 2030 goals [9][75] Question: Competitive landscape in EDC market - Management noted that while one customer returned to a previous provider, overall trends in clinical remain positive with opportunities for growth [11] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry is cautious about making significant changes [28] Question: Demand environment in pharma - Management reported that the industry is healthy, with no significant changes in customer buying behaviors despite external political factors [31] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver moving forward [34][39] Question: Quality cloud expansion - Management highlighted that the quality cloud opportunity is expanding through reaching new customer types and product expansion [80]

Financial Data and Key Metrics Changes - Total revenue for Q3 was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [6] - CRM now constitutes about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [9] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative with significant progress, expected to add value across various product areas including Vault CRM, Crossix, clinical, and safety [6] - Crossix continues to perform well, with expectations for it to remain a growth driver in the coming years [34] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong despite political chaos, with no significant changes in customer buying behaviors noted [31] - Digital marketing spending is increasing, which benefits Crossix as it becomes a standard for measurement and optimization [39] Company Strategy and Development Direction - The company is focused on delivering integrated solutions across clinical operations and clinical data, emphasizing efficiency as a key driver [11] - Veeva aims to be a comprehensive provider in the life sciences sector, integrating software, data, and consulting services [47] Management's Comments on Operating Environment and Future Outlook - Management expresses optimism about the industry, citing ongoing demand for innovative solutions to address uncured diseases [31] - The company anticipates no material impact on its 2030 goals despite some customer attrition in the CRM segment, as the business is diverse and has multiple growth paths [75][76] Other Important Information - The company is investing in product and services teams, with a focus on business consulting and professional services to enhance customer engagement [59] - The partnership with IQVIA is seen as a positive trend, enhancing customer confidence and operational capabilities [42] Q&A Session Summary Question: Concerns about CRM customer migration - Management noted that CRM is currently about 20% of total revenue, down from 25% two years ago, and emphasized that no immediate impact is expected from customer migrations [9][19] Question: Competitive landscape in EDC market - Management acknowledged a competitor winning back a top 20 customer but expressed confidence in their own pipeline and opportunities in the EDC market [10][11] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry remains cautious about significant changes due to the need for relationship building [28] Question: Demand environment and financial health of pharma market - Management reported that the pharmaceutical industry is healthy, with no significant changes in demand or buying behavior observed [31] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver in the future [34][70] Question: Insights from customer-specific factors affecting CRM wins - Management stated that customer-specific dynamics are at play, with no overarching pattern, and emphasized the health of the overall CRM business [56][57]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $811 million, with non-GAAP operating income at $365 million, exceeding guidance [5] - CRM revenue has decreased to about 20% of total revenue, down from 25% two years ago, indicating growth in other product areas [8] Business Line Data and Key Metrics Changes - Veeva AI is highlighted as a major initiative, with significant progress expected to benefit customers and the industry [5] - Crossix continues to perform well, contributing to overall revenue growth, with expectations for it to remain a strong growth driver [32][37] Market Data and Key Metrics Changes - The overall health of the pharmaceutical industry remains strong, with no significant changes in customer buying behaviors noted [28] - Digital marketing spending is increasing, which positively impacts Crossix's performance and growth potential [36] Company Strategy and Development Direction - The company is focused on integrating its software, data, and consulting services to provide comprehensive solutions for life sciences [44] - There is an emphasis on innovation in clinical and safety areas, with expectations for AI to drive efficiency and effectiveness [19][48] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about the industry, citing ongoing demand for solutions to uncured diseases and a stable market environment [28] - The company expects to continue to meet its 2030 goals despite some customer attrition in the CRM segment, due to the diverse nature of its business [73] Other Important Information - The company is investing in hiring for product and services teams to support growth and innovation [55] - The partnership with IQVIA is seen as beneficial, enhancing customer confidence and providing opportunities for joint solutions [40] Q&A Session Summary Question: Concerns about CRM customer migration - Management acknowledged that CRM is currently about 20% of total revenue and that attrition is not expected to impact long-term goals [8][73] Question: Competitive landscape in EDC market - Management noted that while one customer returned to a previous provider, overall trends in clinical operations remain positive, with opportunities for growth [10] Question: Impact of AI on sales force efficiency - Management indicated that while there have been some reductions in sales force size, the industry is cautious about making significant changes [26] Question: Demand environment in pharma - Management reported that the industry is healthy, with no significant changes in customer buying behaviors despite political and economic challenges [28] Question: Crossix performance and future growth - Management confirmed that Crossix continues to perform well and is expected to be a strong growth driver moving forward [32][37] Question: Balancing go-to-market initiatives - Management stated that dedicated teams are in place to focus on various product areas, allowing for simultaneous advancement in multiple initiatives [68]

Veeva Systems, Inc. (NYSE:ESTC) shares dropped after the company released its third-quarter earnings report after Thursday's closing bell. Here's a look at the details in the report. VEEV stock is moving. Watch the price action here.The Details: Veeva reported quarterly earnings of $2.04 per share, which beat the analyst estimate of $1.95.Quarterly revenue of $811.2 million beat the Street estimate of $792.82 million. Subscription services revenues were $682.5 million, up from $580.9 million one year ago, a ...

PLEASANTON, Calif., Nov. 20, 2025 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its third quarter ended October 31, 2025. "Continuing to lead through innovation, Veeva AI delivers on our vision for industry-specific AI that will help the life sciences industry reach new levels of productivity and customer centricity," said CEO Peter Gassner. "Veeva AI is advancing rapidly and our early ado ...

Summary of Veeva's 2025 Investor Day Company Overview - **Company**: Veeva Systems - **Industry**: Life Sciences - **Market Size**: Life sciences is a $2 trillion industry with a total addressable market (TAM) of $20 billion for Veeva's specific software and data solutions [5][26] Core Points and Arguments 1. **Vision and Values**: Veeva aims to build the industry cloud for life sciences, focusing on cloud software, data, and consulting to enhance efficiency and effectiveness in the industry [4][5] 2. **Revenue Goals**: Veeva is on track to achieve a revenue run rate of $6 billion by 2030, implying an annual growth rate of approximately 13% [5][25] 3. **Market Penetration**: Currently, Veeva has a 16% penetration in its TAM, indicating significant growth potential ahead [6][27] 4. **Product Strategy**: Veeva's product offerings include Development Cloud, Quality Cloud, Commercial Cloud, and Data Cloud, all aimed at supporting digital transformation in life sciences [8][9] 5. **AI Integration**: Veeva AI is a major initiative expected to enhance productivity across the life sciences sector, with the first release scheduled for December 2025 [19][20] 6. **Customer Success**: The company emphasizes customer success and product excellence as key drivers for long-term market leadership [10][11] Financial Performance 1. **Revenue Composition**: 92% of Veeva's revenue comes from biopharma, with the top 20 customers accounting for about half of the revenue [24][25] 2. **Operating Margins**: Non-GAAP operating margins were reported at 45% in Q2, with a target of maintaining a floor of 35% by 2030 [26] 3. **Growth Areas**: Each product area is expected to contribute to growth, with clinical operations and data management being key focus areas [27][30] Emerging Market Insights 1. **New Markets Initiative**: Veeva is exploring horizontal enterprise applications as a new market opportunity, focusing on product excellence and innovation [20][21] 2. **Customer Perspective**: Dr. Evan Bailey from Applied Therapeutics highlighted the need for efficiency in drug development and the benefits of integrated systems like Veeva for reducing costs and improving timelines [42][45] Additional Important Insights 1. **Technology as an Enabler**: The integration of technology is seen as crucial for improving efficiency in drug development processes, with a focus on having a single source of truth [46][48] 2. **Cost Savings**: Applied Therapeutics reported significant cost savings by using Veeva's integrated systems, eliminating the need for multiple CROs and reducing database maintenance fees [59][60] 3. **Future Readiness**: Veeva's systems are designed to support future commercial activities, ensuring that all functions are interconnected and ready for market launch [57][58] This summary encapsulates the key points discussed during Veeva's 2025 Investor Day, highlighting the company's strategic direction, financial performance, and insights from industry experts.

Vision and Strategy - Veeva is aiming for \$6 billion in revenue by 2030[8, 13], and is on track to achieve this goal[8, 13, 54, 66, 87] - The company estimates a \$20 billion+ total addressable market (TAM) in Life Sciences[10, 70], with approximately 16% penetrated as of FY26E[10, 70] - Veeva AI is expected to be a significant growth driver[8, 30, 53] Financial Performance and Guidance - Q3'26 total revenue guidance is \$790-\$793 million, with subscription revenue of approximately \$671 million[62] - Q3'26 non-GAAP operating income is projected at \$348-\$350 million, and non-GAAP fully diluted net income per share at \$1.94-\$1.95[62] - The company's revenue run rate today is \$3.2 billion, with a goal of \$6 billion by 2030[67] Market Segmentation and Growth - Biopharma accounts for 92% of Veeva's revenue, MedTech for 5%, and other industries for 3%[65] - The subscription revenue mix is currently 84%, with a target of approximately 87% by 2030[67] - Veeva is experiencing continued adoption in R&D, with an increasing number of customers using multiple products[94, 95]